«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:

2014年第5期

页码:

529-532

栏目:

基础研究

出版日期:

2014-05-25

文章信息/Info

Title:

Effect of rosiglitazone on angiotensin II-induced hypertension and its mechanism in rats

作者:

邹晓译; 张 扬; 张双月; 刘双江; 王雪青

(河北省秦皇岛市第一医院心内科，河北 秦皇岛 066000)

Author(s):

ZOU Xiao-yi;  ZHANG Yang;  ZHANG Shuang-yue;  LIU Shuang-jiang;  WANG Xue-qing

(Department of Cardiology, First Hospital, Qinhuangdao 066000, Hebei, China)

关键词:

罗格列酮; 血管紧张素Ⅱ; 高血压;  超氧阴离子;  NADPH氧化酶; 大鼠

Keywords:

rosiglitazone;  angiotensin II;  hypertension;  superoxide anion;  NADPH oxidase;  rat

分类号:

R544.1

DOI:

-

文献标识码:

A

摘要:

目的:探讨罗格列酮（RSG）对血管紧张素Ⅱ(AngⅡ)诱导高血压大鼠血压的影响及机制。方法: 选择24只SD大鼠随机分为4组:正常对照组、RSG组、AngⅡ组及AngⅡ+RSG组。每组6只大鼠（n=6）。采用alzet渗透泵持续皮下泵入AngⅡ［300 ng/(kg·min)×7 d］建立高血压大鼠模型，RSG组和AngⅡ+RSG组给予RSG灌胃［5 mg/(kg·d)］7 d，7 d后观察各组大鼠的血压、心脏质量指数、空腹血糖变化,测定大鼠主动脉NADPH氧化酶的活性及超氧阴离子的含量。结果: 与AngⅡ组对比，AngⅡ+RSG组血压下降［(136±6) mmHg vs.(166±6) mmHg，P<0.01］及心脏质量指数下降［(3.54±0.04) mg/kg vs.( 3.85±0.08) mg/kg,P<0.01］ ；NADPH氧化酶活性及血管超氧阴离子含量下降［(288.49±36.19) cpm/μg vs.(584.04±69.67) cpm/μg，P<0.01；(2 792.82.7±726.76) cpm/mg vs.(4 765.50±597.34) cpm/mg，P<0.01］。结论: RSG抑制NADPH氧化酶的活性,降低血管超氧阴离子的含量,拮抗血管AngⅡ诱导的血压升高及心肌肥厚,发挥保护心血管的作用。

Abstract:

AIM:To study the effects of rosiglitazone on angiotensin II (AngII)-induced hypertension in rats and to explore the associated mechanism. METHODS: Twenty-four Sprague Dawley rats were divided equally into four groups: control group, rosiglitazone group, AngII group, and AngII+rosiglitazone group. Rosiglitazone ［5 mg/(kg·d)］ was administrated with AngII ［(300 ng/(kg·min) s.c., osmotic pump］ for 7 days in the rats. Rosiglitazone was also given in sham-operated rats. Blood pressure, heart weight index values, vascular superoxide anion production and NADPH oxidase activity were determined. RESULTS: Compared with those in AngII group, blood pressure, heart weight index values, vascular superoxidase production and NADPH oxidase activity all decreased in AngII+rosiglitazone group ［(136±6) mmHg vs.(166±6) mmHg; (3.54±0.04) mg/g vs.(3.85±0.08) mg/g; (288.49±36.19) cpm/μg vs.(584.04±69.67) cpm/μg, respectively, all P<0.01］. CONCLUSION: Rosiglitazone prevents the development of hypertension and myocardial hypertrophy by inhibiting NADPH oxidase activity, reducing superoxide anion production and lowering AngII-induced hypertension.

参考文献/References

[1]van der Meer RW,Rijzewijk LJ,de Jong HW,et al.Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus[J].Circulation,2009,119(15):2069-2077.
[2]Panunti B, Fonseca V.Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients[J].Vascul Pharmacol,2006,45(1):29-35.
[3]Derosa G,Fogari E,Cicero AF,et al.Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin[J].Hypertens Res,2007,30(5):387-394.
[4]Reynolds K,Goldberg RB.Thiazolidinediones:beyond glycemic control[J].Treat Endocrinol,2006,5(1):25-36.
[5]van Tits LJ,Arioglu-Oral E,Sweep CG,et al.Anti-inflammatory effects of troglitazone in nondiabetic obese subjects Independent of changes in insulin sensitivity[J].Neth J Med,2005, 63(7):250-255.
[6]Datla SR,Griendling KK.Reactive Oxygen species,NADPH oxidases,and hypertension[J]. Hypertension,2010,56(3):325-330.
[7]Paravicini TM,Touyz RM.NADPH oxidases,reactive Oxygen species,and hypertension:clinical implications and therapeutic possibilities[J].Diabetes Care,2008,31(Suppl 2):S170-S180.
[8]Brandes RP,Weissmann N,Schr?der K.NADPH oxidases in cardiovascular disease[J].Free Radic Biol Med,2010,49(5): 687-706.
[9]Kase H,Hashikabe Y,Uchida K,et al.Supplementation with tetrahydrobiopterin prevents the cardiovascular effects of angiotensin II-induced oxidative and nitrosative stress[J].J Hypertens, 2005, 23(7):1375-1382.
[10]Bradford MM.A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding[J].Anal Biochem,1976,72:248-254.
[11]Wu L,Wang R,De Champlain J,et al.Beneficial and deleterious effects of rosiglitazone on hypertension development in spontaneously hypertensive rats[J].Am J Hypertens,2004,17(9):749-756.
[12]Kleinhenz JM,Kleinhenz DJ,You S,et al.Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production[J].Am J Physiol Heart Circ Physiol,2009,297(5):H1647-H1654.
[13]Zhou MS,Jaimes EA,Raij L.Vascular but not cardiac remodeling is associated with superoxide production in angiotensin II hypertension[J].J Hypertens,2005,23(9):1737-1743.
[14]Landmesser U,Dikalov S,Price SR,et al.Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial nitric oxide synthase in hypertension:role of the NAD(P)H Oxidase[J].J Clin Invest,2003,111(8):1201-1209.
[15]Landmesser U,Drexler H.Effect of angiotensin II type 1 receptor antagonism on endothelial function:role of bradykinin and nitric oxide[J].J Hypertens Suppl,2006,24(1):S39-S43.
[16]Fukui T,Ishizaka N,Rajagopalan S,et al.p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats[J].Circ Res,1997,80(1):45-51.

备注/Memo

备注/Memo:

收稿日期：2013-12-25.
作者简介：邹晓译，主治医师，硕士 Email：zouxiaoyi80@163.com

常用功能

更新日期/Last Update: 2014-06-05